Lupin shares jump 2% after signing Canada licensing deal for novel antidepressant DeslaFlex
News by Aliceblue News Desk
17 Feb 2026
Introduction
Leading global pharma company signed licence and supply agreement with Spektus Pharma to commercialize antidepressant DeslaFlex in Canada for Major Depressive Disorder treatment.
Also Read: Ashoka Buildcon secures major overseas road contract worth $45 million
Share price movement of Lupin
On February 17, 2026, Lupin Ltd opened at ₹2,235.00, up 0.65% from its previous close of ₹2,220.50. The stock reached a high of ₹2,261.95 (1.87%) and a low of ₹2,230.00. By 11:15 AM, it traded at ₹2,252.05, a 1.42% increase, with a market cap of ₹1,02,911.47 crore.
Lupin Signs DeslaFlex Canada Deal
Lupin Limited has signed a licence and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex in Canada. The announcement was made on February 16, 2026.
DeslaFlex is developed by Spektus using its proprietary Flexitab oral drug delivery platform. The product is indicated for the management of Major Depressive Disorder.
The agreement combines Lupin’s commercial presence in Canada with Spektus’s formulation capabilities. The partnership aims to strengthen Lupin’s CNS portfolio with differentiated therapies.
Stock performance of Lupin for period of 1 week, 6 months, and 1 year
Lupin Ltd gained 0.79% over the past week and rose 13.2% in the past six months. The stock advanced 9.60% over the past one year.
Also Read: Zydus Lifesciences gets USFDA final approval for Ammonium Lactate Cream
Shareholding pattern of Lupin
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 46.90% | 46.90% | 46.90% |
| FII | 21.50% | 20.50% | 21.30% |
| DII | 25.60% | 26.60% | 25.60% |
| Public | 6.00% | 6.10% | 6.30% |
About Lupin
Lupin Limited (NSE: LUPIN) is a Mumbai-based global pharmaceutical company operating in over 100 markets with branded, generic, biotechnology products and active pharmaceutical ingredients.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Lupin Ltd share price rising today?
A: Lupin Ltd signed licence and supply agreement with Spektus to commercialize antidepressant DeslaFlex in Canada for Major Depressive Disorder.
Q: What is Lupin Ltd’s main business focus?
A: Lupin Ltd develops and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients across global markets.
Q: What are the 52-week high and low of Lupin Ltd stock?
A: Lupin Ltd 52-week high stands at Rs 2,261.95, while 52-week low is Rs 1,774.00.
News Author
Aliceblue News Desk
